BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members
17 févr. 2022 17h42 HE | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
TuftsCSDD-Logo-Color.jpg
Protocol Design Optimization Is Starting to Improve Clinical Study Performance, According to the Tufts Center for the Study of Drug Development
09 sept. 2014 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...
TuftsCSDD-Logo-Color.jpg
Drug Company Collaborations to Reduce Development Risk Are Increasing, According to Tufts Center for the Study of Drug Development
07 août 2014 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...
TuftsCSDD-Logo-Color.jpg
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
10 juil. 2014 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...
TuftsCSDD-Logo-Color.jpg
Risk-Sharing Drug Development Programs Experience Longer Development Times, According to the Tufts Center for the Study of Drug Development
08 mai 2014 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...
TuftsCSDD-Logo-Color.jpg
Drug Developers Circumspect About Using Social Media in Clinical Research, According to the Tufts Center for the Study of Drug Development
06 mars 2014 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 6, 2014) - Social media is gaining ground as an important tool to improve the clinical research process through more effective engagement of patient communities, but...
TuftsCSDD-Logo-Color.jpg
New Breakthrough Therapy Designation Has Potential to Shorten Development Time Considerably, According to the Tufts Center for the Study of Drug Development
23 janv. 2014 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 23, 2014) - The recently launched Breakthrough Therapy Designation (BTD) program in the United States, aimed at expediting development and review of drugs intended to...
TuftsCSDD-Logo-Color.jpg
Drug Developers Are Implementing New Strategies for Use of Comparator Drugs in Clinical Trials, According to Tufts Center for the Study of Drug Development
16 janv. 2014 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 16, 2014) - Drug developers are aggressively implementing new strategies to improve their access to and use of comparator drugs, which are used in clinical trials to...
TuftsCSDD-Logo-Color.jpg
Drug Company Success Depends on New Development Paradigms, According to Tufts Center for the Study of Drug Development
07 janv. 2014 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 7, 2014) - While many drug developers continue to improve clinical trial operational efficiency to increase the pace of new product introductions, their medium- and...
TuftsCSDD-Logo-Color.jpg
Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically According to the Tufts Center for the Study of Drug Development
14 nov. 2013 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 14, 2013) - The pharmaceutical industry, especially Big Pharma, has dramatically shifted its R&D focus from its historical concentration on small molecule drugs...